Results 31 to 40 of about 1,392 (217)

²²⁵Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

Pharmaceutics, 2023
The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially
Léa Rubira, Emmanuel Deshayes, Lore Santoro, Pierre Olivier Kotzki, Cyril Fersing   +4 more
doaj   +1 more source

Supply and Clinical Application of Actinium-225 and Bismuth-213.

Semin Nucl Med, 2020
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia.
Morgenstern A, Apostolidis C, Bruchertseifer F.   +2 more
europepmc   +3 more sources

Advances in ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

Pharmaceutics, 2022
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited.
Sui Wai Ling, Erik de Blois, Eline Hooijman, Astrid van der Veldt, Tessa Brabander   +4 more
doaj   +1 more source

Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging

EJNMMI Radiopharmacy and Chemistry, 2022
Background Combining optical (fluorescence) imaging with nuclear imaging has the potential to offer a powerful tool in personal health care, where nuclear imaging offers in vivo functional whole-body visualization, and the fluorescence modality may be ...
Anthony W. McDonagh, Brooke L. McNeil, Julie Rousseau, Ryan J. Roberts, Helen Merkens, Hua Yang, François Bénard, Caterina F. Ramogida   +7 more
doaj   +1 more source

Spectroscopic and computational investigation of actinium coordination chemistry

Nature Communications, 2016
Actinium-225 is a promising isotope for α-therapy but progress in developing its chemistry is hindered by its high radioactivity and short supply. Here, the authors characterize actinium coordination in HCl solutions using X-ray absorption spectroscopy ...
Maryline G. Ferrier, Enrique R. Batista, John M. Berg, Eva R. Birnbaum, Justin N. Cross, Jonathan W. Engle, Henry S. La Pierre, Stosh A. Kozimor, Juan S. Lezama Pacheco, Benjamin W. Stein, S. Chantal E. Stieber, Justin J. Wilson   +11 more
doaj   +1 more source

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

EJNMMI Radiopharmacy and Chemistry, 2023
Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist,
Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille   +9 more
doaj   +1 more source

Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free ²²⁵Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy

Pharmaceutics, 2021
Actinium-225 (225Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although 225Ac labeling of bifunctional chelating ligands is effective, previous in vivo studies reported that free 225Ac can be released from the drugs and that such ...
Mitsuyoshi Yoshimoto, Yukie Yoshii, Hiroki Matsumoto, Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Fukiko Hihara, Tomoko Tachibana, Ayano Doi, Tatsuya Higashi, Hirofumi Fujii, Kohshin Washiyama   +11 more
doaj   +1 more source

Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

EJNMMI Physics, 2021
Background Actinium-225 is an alpha-particle emitter under investigation for use in radiopharmaceutical therapy. To address limited supply, accelerator-produced 225Ac has been recently made available.
George Sgouros, Bin He, Nitya Ray, Dale L. Ludwig, Eric C. Frey   +4 more
doaj   +1 more source

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?

Frontiers in Medicine, 2022
Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation are locally delivered to tumor cells, while the surrounding healthy tissue is minimally affected.
Roger M. Pallares, Rebecca J. Abergel, Rebecca J. Abergel   +2 more
doaj   +1 more source

Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers

Bioengineering & Translational Medicine, 2022
Partial and/or heterogeneous irradiation of established (i.e., large, vascularized) tumors by α‐particles that exhibit only a 4–5 cell‐diameter range in tissue, limits the therapeutic effect, since regions not being hit by the high energy α‐particles are
Dominick Salerno, Alaina Howe, Omkar Bhatavdekar, Anders Josefsson, Jesus Pacheco‐Torres, Zaver M. Bhujwalla, Kathleen L. Gabrielson, Stavroula Sofou   +7 more
doaj   +1 more source